Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Source: View publication →
In patients with previously untreated advanced clear-cell renal-cell carcinoma, the combination of pembrolizumab and axitinib significantly improved overall survival, progression-free survival, and objective response rate compared to sunitinib monotherapy.
Key Findings
Study Design
Study Limitations
Clinical Significance
The KEYNOTE-426 trial established pembrolizumab plus axitinib as a highly effective new standard-of-care first-line therapy for patients with advanced clear-cell renal cell carcinoma. Unlike prior immune combination regimens (such as nivolumab plus ipilimumab) which primarily demonstrated a survival advantage in intermediate- and poor-risk patients, pembrolizumab plus axitinib proved efficacious across all IMDC risk categories, including favorable-risk patients. This broadened the applicability of frontline immunotherapy combinations in advanced RCC.
Historical Context
For over a decade, antiangiogenic vascular endothelial growth factor (VEGF) targeted therapies like sunitinib and pazopanib were the definitive first-line standard for advanced clear-cell renal-cell carcinoma. The RCC treatment paradigm shifted with the introduction of immune checkpoint inhibitors, first proving effective as monotherapy in the second-line setting, and then as a dual-immunotherapy combination (CheckMate 214) in the first-line setting for specific risk groups. KEYNOTE-426 represented a major milestone by demonstrating that rationally combining a PD-1 inhibitor (pembrolizumab) with a potent, selective VEGF tyrosine kinase inhibitor (axitinib) could successfully yield an unprecedented survival benefit over sunitinib across the entire spectrum of patients, ushering in the era of IO-TKI combinations as standard upfront therapy.
Guided Discussion
High-yield insights from every perspective
How do the mechanisms of action of pembrolizumab and axitinib complement each other in the treatment of clear-cell renal cell carcinoma, and why is this specific histology particularly susceptible to angiogenesis inhibition?
Key Response
Pembrolizumab is a PD-1 inhibitor that restores T-cell mediated antitumor immunity. Axitinib is a highly selective VEGFR tyrosine kinase inhibitor. Clear-cell RCC is typically driven by VHL tumor suppressor gene inactivation, leading to HIF accumulation and massive VEGF production. Combining these tackles both the immune evasion and the hallmark aberrant angiogenesis of this cancer.
When treating a patient with pembrolizumab and axitinib who develops Grade 3 AST/ALT elevation, how do you clinically differentiate between TKI-induced hepatotoxicity and immune-mediated hepatitis, and how does this affect your sequencing of management?
Key Response
Both drugs can cause hepatotoxicity. TKI toxicity often resolves rapidly with holding the drug, whereas immune-mediated hepatitis requires systemic corticosteroids and possibly permanent discontinuation of the IO agent. Residents must know to first hold both drugs; if enzymes do not improve quickly, assume immune-mediated etiology and initiate steroids.
The KEYNOTE-426 trial demonstrated benefit across all IMDC risk groups, contrasting with CheckMate 214 (ipilimumab/nivolumab) which primarily benefited intermediate/poor-risk patients. How does this data influence your choice between IO-TKI versus IO-IO frontline regimens for a patient with favorable-risk advanced RCC?
Key Response
Favorable-risk RCC is often heavily angiogenesis-driven, making it responsive to VEGFR TKIs. CheckMate 214 did not show an OS benefit in favorable risk, but KEYNOTE-426 did. Fellows must weigh the high objective response rate and PFS of IO-TKI against the potentially higher complete response rate and durable off-treatment survival offered by IO-IO therapy.
Given the high objective response rate of the pembrolizumab-axitinib combination seen in this trial, how does this highly active upfront systemic regimen alter our surgical approach to cytoreductive nephrectomy in the modern era?
Key Response
The CARMENA trial previously questioned upfront cytoreductive nephrectomy in the TKI era. With even higher response rates and profound primary tumor shrinkage from IO-TKI combinations, attendings must reconsider patient selection, often favoring upfront systemic therapy and reserving nephrectomy for consolidation in excellent responders or for palliation.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
In KEYNOTE-426, the control arm was standard-of-care sunitinib, but crossover to subsequent immuno-oncology therapies was expected upon progression. How does the choice of statistical methods to adjust for crossover, such as Inverse Probability of Censoring Weighting, impact the interpretation of the overall survival benefit?
Key Response
Subsequent salvage therapies in the control arm can dilute the OS benefit of the experimental arm. PhD researchers must evaluate how handling subsequent treatments affects the magnitude of the survival curves and whether the trial's statistical plan adequately addressed informative censoring to estimate the true treatment effect.
The trial utilized an open-label design for the administration of axitinib and sunitinib. As a peer reviewer, how would you critically evaluate the potential for performance and detection biases in the assessment of Progression-Free Survival, despite the implementation of blinded independent central review?
Key Response
Even with blinded independent imaging review, open-label designs can introduce biases regarding asymmetric scan timing, symptom reporting, dose modifications, and early withdrawal due to perceived lack of efficacy or toxicities, which a stringent reviewer would flag as potential confounders for PFS.
Based on KEYNOTE-426 alongside subsequent trials like CheckMate 9ER and CLEAR, should guidelines issue a uniform Category 1 recommendation for all IO-TKI combinations across all IMDC risk groups, or is there sufficient evidence to prioritize specific regimens based on comparative toxicity profiles?
Key Response
Current NCCN and EAU guidelines recommend several IO-TKI regimens as preferred Category 1 options for first-line clear-cell RCC. The committee must evaluate whether to distinguish between these based on differing overlapping toxicities, quality of life data, and long-term CR rates, especially given the absence of head-to-head randomized trials among the combinations.
Clinical Landscape
Noteworthy Related Trials
CheckMate 214
Tested
Nivolumab plus Ipilimumab
Population
Previously untreated advanced renal-cell carcinoma
Comparator
Sunitinib
Endpoint
Overall survival and objective response rate in intermediate or poor-risk patients
JAVELIN Renal 101
Tested
Avelumab plus Axitinib
Population
Previously untreated advanced clear-cell renal-cell carcinoma
Comparator
Sunitinib
Endpoint
Progression-free survival and overall survival in PD-L1 positive patients
CheckMate 9ER
Tested
Nivolumab plus Cabozantinib
Population
Previously untreated advanced renal-cell carcinoma
Comparator
Sunitinib
Endpoint
Progression-free survival
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis